Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)

NCT00273338 is registered in ClinicalTrials.gov with Novacea as lead sponsor.

NCT NCT00273338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00273338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
Lead sponsor
Novacea
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2006
Completion date
November 30, 2007
Enrollment
1,200 (estimated)
Sites
222

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer